30% off. Use code SUMMERSALE30 at checkout for 30% off for 12 months on Plus, Pro and Premium subscriptions. Subscribe now
United States Pharmaceuticals

EyePoint Inc (EYPT)

Track

Over the last 90 days, EyePoint Inc. has seen significant insider selling, with a net value of -$168,312. The total value of sell transactions was $180,952, while buy transactions totaled $19,724. This activity occurred against a backdrop of a 7.1% stock price decrease over the same period. The last earnings report missed expectations by 22.22%.
Stock chart
Ticker: EYPT Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


Subscribe to get access to the transaction volume chart and in-chart transaction details
• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Activity signal Earnings
Top insiders
Trades
Ribeiro Ramiro
Chief Medical Officer
1 sale — total 36,555 USD
Sale 17 Apr 2026
Value US$4,643,117.34 | Price 282.41 | Shares 89,536
Proposed sale 17 Apr 2026
Value US$2,390,595.10 | Price 296.66 | Shares 95,210
Buy 16 Mar 2026
Value US$19,723.80 | Price 13.15 | Shares 1,500
Sale 4 Mar 2026
Value US$43,571.69 | Price 17.87 | Shares 2,438
Sale 17 Feb 2026
Value US$36,555.00 | Price 15.00 | Shares 2,437
Sale 5 Jan 2026
Value US$727,319.46 | Price 17.10 | Shares 42,544
Proposed sale 5 Jan 2026
Value US$940,284.16 | Price 17.48 | Shares 53,792
Sale 4 Dec 2025
Value US$942,240.00 | Price 15.70 | Shares 60,000
Sale 4 Dec 2025
Value US$140,477.43 | Price 15.11 | Shares 9,300
Proposed sale 4 Dec 2025
Value US$140,477.43 | Price 15.11 | Shares 9,300
Sale 28 Nov 2025
Value US$7,475.00 | Price 14.95 | Shares 500
Proposed sale 28 Nov 2025
Value US$7,475.00 | Price 14.95 | Shares 500
Sale 26 Nov 2025
Value US$2,990.00 | Price 14.95 | Shares 200
Proposed sale 26 Nov 2025
Value US$2,990.00 | Price 14.95 | Shares 200
Proposed sale 11 Nov 2025
Value US$30,894.70 | Price 11.35 | Shares 2,722
Planned sale 11 Nov 2025
Value US$31,602.42 | Price 11.61 | Shares 2,722
Buy 19 May 2025
Value US$29,950.00 | Price 5.99 | Shares 5,000
Buy 16 May 2025
Value US$29,050.00 | Price 5.81 | Shares 5,000
Buy 15 May 2025
Value US$27,350.00 | Price 5.47 | Shares 5,000
Buy 14 May 2025
Value US$27,100.00 | Price 5.42 | Shares 5,000
Proposed sale 23 Oct 2024
Value US$673,354.52 | Price 10.04 | Shares 67,100
Proposed sale 14 Oct 2024
Value US$329,817.00 | Price 8.92 | Shares 36,975
Buy 21 Aug 2024
Value US$39,750.00 | Price 7.95 | Shares 5,000
Buy 20 Aug 2024
Value US$19,996.93 | Price 7.79 | Shares 2,567
Buy 19 Aug 2024
Value US$99,750.00 | Price 7.98 | Shares 12,500
Buy 16 Aug 2024
Value US$25,003.24 | Price 7.88 | Shares 3,173
Sale 12 Jul 2024
Value US$116,995.16 | Price 10.06 | Shares 11,625
Sale 3 Jun 2024
Value US$119,704.95 | Price 10.30 | Shares 11,625
Sale 14 May 2024
Value US$147,044.62 | Price 12.65 | Shares 11,625
Proposed sale 14 May 2024
Value US$897,407.00 | Price 12.49 | Shares 71,850
Buy 6 May 2024
Value US$2,560,411.08 | Price 12.36 | Shares 207,153
Buy 6 May 2024
Value US$7,521,309.90 | Price 11.70 | Shares 642,847
Buy 18 Apr 2024
Value US$3,525,246.90 | Price 18.90 | Shares 186,521
Buy 18 Apr 2024
Value US$6,964,199.28 | Price 17.62 | Shares 395,244
Sale 2 Feb 2024
Value US$5,954.41 | Price 28.49 | Shares 209
Proposed sale 2 Feb 2024
Value US$288,065.04 | Price 28.51 | Shares 10,104
Sale 26 Jan 2024
Value US$867,671.61 | Price 25.77 | Shares 33,665
Sale 26 Jan 2024
Value US$396,571.62 | Price 25.41 | Shares 15,609
Sale 26 Jan 2024
Value US$1,295.74 | Price 25.41 | Shares 51
Sale 26 Jan 2024
Value US$242,717.09 | Price 25.27 | Shares 9,604
Sale 26 Jan 2024
Value US$417,653.40 | Price 25.45 | Shares 16,413
Sale 25 Jan 2024
Value US$7,500.00 | Price 25.00 | Shares 300
Sale 25 Jan 2024
Value US$7,500.00 | Price 25.00 | Shares 300
Sale 25 Jan 2024
Value US$7,500.00 | Price 25.00 | Shares 300
Sale 25 Jan 2024
Value US$7,500.00 | Price 25.00 | Shares 300
Sale 24 Jan 2024
Value US$140,067.76 | Price 25.01 | Shares 5,600
Sale 24 Jan 2024
Value US$142,553.58 | Price 25.01 | Shares 5,700
Sale 24 Jan 2024
Value US$141,363.16 | Price 25.02 | Shares 5,651
Sale 24 Jan 2024
Value US$140,052.08 | Price 25.01 | Shares 5,600
Sale 24 Jan 2024
Value US$748,249.95 | Price 24.98 | Shares 29,956
Proposed sale 24 Jan 2024
Value US$748,249.95 | Price 24.98 | Shares 29,956
Proposed sale 24 Jan 2024
Value US$857,950.22 | Price 24.91 | Shares 34,442
Sale 23 Jan 2024
Value US$77,400.00 | Price 25.00 | Shares 3,096
Sale 23 Jan 2024
Value US$50,975.00 | Price 25.00 | Shares 2,039
Sale 23 Jan 2024
Value US$125,949.69 | Price 24.97 | Shares 5,044
Proposed sale 23 Jan 2024
Value US$125,949.69 | Price 24.97 | Shares 5,044
Sale 23 Jan 2024
Value US$12,500.00 | Price 25.00 | Shares 500
Sale 23 Jan 2024
Value US$10,000.00 | Price 25.00 | Shares 400
Proposed sale 23 Jan 2024
Value US$1,590,137.78 | Price 23.98 | Shares 66,311
Sale 22 Jan 2024
Value US$652,254.12 | Price 22.69 | Shares 28,750
Sale 22 Jan 2024
Value US$120,437.22 | Price 22.24 | Shares 5,416
Proposed sale 22 Jan 2024
Value US$860,235.12 | Price 22.32 | Shares 38,541
Sale 11 Jan 2024
Value US$37,159,225.00 | Price 19.45 | Shares 1,910,500
Sale 11 Jan 2024
Value US$37,159,225.00 | Price 19.45 | Shares 1,910,500
Proposed sale 11 Jan 2024
Value US$37,159,225.00 | Price 19.45 | Shares 1,910,500
Buy 11 Jan 2024
Value US$14,812,500.00 | Price 19.75 | Shares 750,000
Buy 9 Jan 2024
Value US$2,238,600.00 | Price 21.32 | Shares 105,000
Sale 8 Jan 2024
Value US$484,124.19 | Price 21.13 | Shares 22,913
Sale 13 Dec 2023
Value US$29,160.00 | Price 20.00 | Shares 1,458
Buy 8 Dec 2023
Value US$9,999,995.00 | Price 17.00 | Shares 588,235
Sale 6 Dec 2023
Value US$4,901,515.22 | Price 18.41 | Shares 266,242
Sale 6 Dec 2023
Value US$4,901,515.22 | Price 18.41 | Shares 266,242
Sale 5 Dec 2023
Value US$14,609,121.78 | Price 19.91 | Shares 733,758
Sale 5 Dec 2023
Value US$14,609,121.78 | Price 19.91 | Shares 733,758
Proposed sale 5 Dec 2023
Value US$18,340,000.00 | Price 18.34 | Shares 1,000,000
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-04-20 2026-04-17 S Sale
3.7
Ribeiro Ramiro

Chief Medical Officer

Officer
89,536 -44.2%
282.41
US$4,643,117 		89,536 -44.2% 282.41 US$4,643,117
2026-04-17 2026-04-17 PrS Proposed sale
3.7
Ramiro Ribeiro

Officer

Officer
95,210
296.66
US$2,390,595 		95,210 296.66 US$2,390,595
2026-03-16 2026-03-16 B Purchase
1.4
Duker Jay S.

President and CEO

Executive Director
37,328 -18.5%
24.94
US$3,189,067 		37,328 -18.5% 24.94 US$3,189,067
2026-03-05 2026-03-04 S Sale
3.7
Ribeiro Ramiro

Chief Medical Officer

Officer
2,438 -100.0%
17.87
US$43,572 		2,438 -100.0% 17.87 US$43,572
2026-02-18 2026-02-17 S Sale
3.7
Ribeiro Ramiro

Chief Medical Officer

Officer
2,437 -100.0%
15.00
US$36,555 		2,437 -100.0% 15.00 US$36,555
2026-01-07 2026-01-05 S Sale
3.7
Ribeiro Ramiro

Chief Medical Officer

Officer
42,544 -100.0%
17.10
US$727,319 		42,544 -100.0% 17.10 US$727,319
2026-01-05 2026-01-05 PrS Proposed sale
3.7
Ramiro Ribeiro

Officer

Officer
53,792
17.48
US$940,284 		53,792 17.48 US$940,284
2025-12-08 2025-12-04 S Sale
3.8
Cormorant Asset Management, LP

Former 10% Owner
60,000 -0.7%
15.70
US$942,240 		60,000 -0.7% 15.70 US$942,240
2025-12-05 2025-12-04 S Sale
3.4
Lurker Nancy
Non-Executive Director
9,300 -4.3%
15.11
US$140,477 		9,300 -4.3% 15.11 US$140,477
2025-12-04 2025-12-04 PrS Proposed sale
3.4
Lurker Nancy

Officer

Officer
9,300
15.11
US$140,477 		9,300 15.11 US$140,477
2025-12-01 2025-11-28 S Sale
3.4
Lurker Nancy
Non-Executive Director
500 -0.2%
14.95
US$7,475 		500 -0.2% 14.95 US$7,475
2025-11-28 2025-11-28 PrS Proposed sale
3.4
Lurker Nancy

Officer

Officer
500
14.95
US$7,475 		500 14.95 US$7,475
2025-12-01 2025-11-26 S Sale
3.4
Lurker Nancy
Non-Executive Director
200 -0.1%
14.95
US$2,990 		200 -0.1% 14.95 US$2,990
2025-11-26 2025-11-26 PrS Proposed sale
3.4
Lurker Nancy

Officer

Officer
200
14.95
US$2,990 		200 14.95 US$2,990
2025-11-12 2025-11-11 PrS Proposed sale
3.7
Ramiro Ribeiro

Officer

Officer
2,722
11.35
US$30,895 		2,722 11.35 US$30,895
2025-11-12 2025-11-11 PlS Planned sale
3.7
Ribeiro Ramiro

Chief Medical Officer

Officer
2,722 -100.0%
11.61
US$31,602 		2,722 -100.0% 11.61 US$31,602
2025-05-19 2025-05-19 B Purchase
3.7
Zaderej Karen L.
Non-Executive Director
5,000 +15.9%
5.99
US$29,950 		5,000 +15.9% 5.99 US$29,950
2025-05-19 2025-05-16 B Purchase
3.7
Zaderej Karen L.
Non-Executive Director
5,000 +18.9%
5.81
US$29,050 		5,000 +18.9% 5.81 US$29,050
2025-05-15 2025-05-15 B Purchase
3.7
Zaderej Karen L.
Non-Executive Director
5,000 +23.3%
5.47
US$27,350 		5,000 +23.3% 5.47 US$27,350
2025-05-15 2025-05-14 B Purchase
3.7
Zaderej Karen L.
Non-Executive Director
5,000 +30.3%
5.42
US$27,100 		5,000 +30.3% 5.42 US$27,100
2024-10-23 2024-10-23 PrS Proposed sale
ANTHONY P. ADAMIS

Director

Non-Executive Director
67,100
10.04
US$673,355 		67,100 10.04 US$673,355
2024-10-15 2024-10-14 PrS Proposed sale
3.7
David R. Guyer

Former Director

Non-Executive Director
36,975
8.92
US$329,817 		36,975 8.92 US$329,817
2024-08-21 2024-08-21 B Purchase
3.7
ANDO GORAN
Non-Executive Director
5,000 +61.3%
7.95
US$39,750 		5,000 +61.3% 7.95 US$39,750
2024-08-21 2024-08-20 B Purchase
2.4
DICICCO WENDY F
Non-Executive Director
2,567 +34.7%
7.79
US$19,997 		2,567 +34.7% 7.79 US$19,997
2024-08-21 2024-08-19 B Purchase
3.7
Zaderej Karen L.
Non-Executive Director
12,500 +312.5%
7.98
US$99,750 		12,500 +312.5% 7.98 US$99,750
2024-08-20 2024-08-16 B Purchase
3.4
Lurker Nancy
Non-Executive Director
3,173 +3.4%
7.88
US$25,003 		3,173 +3.4% 7.88 US$25,003
2024-07-16 2024-07-12 S Sale
3.7
GUYER DAVID R
Non-Executive Director
11,625 -86.3%
10.06
US$116,995 		11,625 -86.3% 10.06 US$116,995
2024-06-04 2024-06-03 S Sale
3.7
GUYER DAVID R
Non-Executive Director
11,625 -75.9%
10.30
US$119,705 		11,625 -75.9% 10.30 US$119,705
2024-05-16 2024-05-14 S Sale
3.7
GUYER DAVID R
Non-Executive Director
11,625 -67.7%
12.65
US$147,045 		11,625 -67.7% 12.65 US$147,045
2024-05-14 2024-05-14 PrS Proposed sale
3.7
David R. Guyer

Director

Non-Executive Director
71,850
12.49
US$897,407 		71,850 12.49 US$897,407
2024-05-08 2024-05-06 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
207,153 +2.6%
12.36
US$2,560,411 		207,153 +2.6% 12.36 US$2,560,411
2024-05-08 2024-05-06 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
642,847 +8.6%
11.70
US$7,521,310 		642,847 +8.6% 11.70 US$7,521,310
2024-04-22 2024-04-18 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
186,521 +2.6%
18.90
US$3,525,247 		186,521 +2.6% 18.90 US$3,525,247
2024-04-22 2024-04-18 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
395,244 +5.7%
17.62
US$6,964,199 		395,244 +5.7% 17.62 US$6,964,199
2024-02-05 2024-02-02 S Sale
2.8
Jones David Scott

SVP & Chief Commercial Officer

Officer
209 -0.5%
28.49
US$5,954 		209 -0.5% 28.49 US$5,954
2024-02-02 2024-02-02 PrS Proposed sale
2.8
DAVID S JONES

Officer

Officer
10,104
28.51
US$288,065 		10,104 28.51 US$288,065
2024-01-30 2024-01-26 S Sale
2.9
Paggiarino Dario A.

Chief Medical Officer

Officer
33,665 -48.0%
25.77
US$867,672 		33,665 -48.0% 25.77 US$867,672
2024-01-30 2024-01-26 S Sale
2.9
Paggiarino Dario A.

Chief Medical Officer

Officer
15,609 -18.2%
25.41
US$396,572 		15,609 -18.2% 25.41 US$396,572
2024-01-30 2024-01-26 S Sale
2.9
Paggiarino Dario A.

Chief Medical Officer

Officer
51 -0.1%
25.41
US$1,296 		51 -0.1% 25.41 US$1,296
2024-01-29 2024-01-26 S Sale
2.8
Jones David Scott

SVP & Chief Commercial Officer

Officer
9,604 -20.2%
25.27
US$242,717 		9,604 -20.2% 25.27 US$242,717
2024-01-29 2024-01-26 S Sale
2.8
Jones David Scott

SVP & Chief Commercial Officer

Officer
16,413 -25.7%
25.45
US$417,653 		16,413 -25.7% 25.45 US$417,653
2024-01-29 2024-01-25 S Sale
2.9
Paggiarino Dario A.

Chief Medical Officer

Officer
300 -0.8%
25.00
US$7,500 		300 -0.8% 25.00 US$7,500
2024-01-29 2024-01-25 S Sale
2.9
Paggiarino Dario A.

Chief Medical Officer

Officer
300 -0.8%
25.00
US$7,500 		300 -0.8% 25.00 US$7,500
2024-01-26 2024-01-25 S Sale
2.8
Jones David Scott

SVP & Chief Commercial Officer

Officer
300 -0.8%
25.00
US$7,500 		300 -0.8% 25.00 US$7,500
2024-01-26 2024-01-25 S Sale
2.8
Jones David Scott

SVP & Chief Commercial Officer

Officer
300 -0.8%
25.00
US$7,500 		300 -0.8% 25.00 US$7,500
2024-01-26 2024-01-24 S Sale
2.8
Jones David Scott

SVP & Chief Commercial Officer

Officer
5,600 -12.9%
25.01
US$140,068 		5,600 -12.9% 25.01 US$140,068
2024-01-26 2024-01-24 S Sale
2.8
Jones David Scott

SVP & Chief Commercial Officer

Officer
5,700 -11.6%
25.01
US$142,554 		5,700 -11.6% 25.01 US$142,554
2024-01-25 2024-01-24 S Sale
2.9
Paggiarino Dario A.

Chief Medical Officer

Officer
5,651 -13.4%
25.02
US$141,363 		5,651 -13.4% 25.02 US$141,363
2024-01-25 2024-01-24 S Sale
2.9
Paggiarino Dario A.

Chief Medical Officer

Officer
5,600 -11.7%
25.01
US$140,052 		5,600 -11.7% 25.01 US$140,052
2024-01-25 2024-01-24 S Sale
3.4
Lurker Nancy

Executive Vice Chair

Executive Director
29,956 -18.1%
24.98
US$748,250 		29,956 -18.1% 24.98 US$748,250
2024-01-24 2024-01-24 PrS Proposed sale
3.4
Lurker Nancy

Director

Non-Executive Director
29,956
24.98
US$748,250 		29,956 24.98 US$748,250
2024-01-24 2024-01-24 PrS Proposed sale
2.8
DAVID S JONES

Officer

Officer
34,442
24.91
US$857,950 		34,442 24.91 US$857,950
2024-01-25 2024-01-23 S Sale
2.9
Paggiarino Dario A.

Chief Medical Officer

Officer
3,096 -7.8%
25.00
US$77,400 		3,096 -7.8% 25.00 US$77,400
2024-01-25 2024-01-23 S Sale
2.9
Paggiarino Dario A.

Chief Medical Officer

Officer
2,039 -4.9%
25.00
US$50,975 		2,039 -4.9% 25.00 US$50,975
2024-01-25 2024-01-23 S Sale
3.4
Lurker Nancy

Executive Vice Chair

Executive Director
5,044 -3.0%
24.97
US$125,950 		5,044 -3.0% 24.97 US$125,950
2024-01-24 2024-01-23 S Sale
2.8
Jones David Scott

SVP & Chief Commercial Officer

Officer
500 -1.3%
25.00
US$12,500 		500 -1.3% 25.00 US$12,500
2024-01-24 2024-01-23 S Sale
2.8
Jones David Scott

SVP & Chief Commercial Officer

Officer
400 -1.0%
25.00
US$10,000 		400 -1.0% 25.00 US$10,000
2024-01-23 2024-01-23 PrS Proposed sale
3.4
Lurker Nancy

Director

Non-Executive Director
5,044
24.97
US$125,950 		5,044 24.97 US$125,950
2024-01-23 2024-01-23 PrS Proposed sale
2.9
DARIO A PAGGIARINO

Officer

Officer
66,311
23.98
US$1,590,138 		66,311 23.98 US$1,590,138
2024-01-24 2024-01-22 S Sale
2.8
Jones David Scott

SVP & Chief Commercial Officer

Officer
28,750 -43.1%
22.69
US$652,254 		28,750 -43.1% 22.69 US$652,254
2024-01-24 2024-01-22 S Sale
2.8
Jones David Scott

SVP & Chief Commercial Officer

Officer
5,416 -7.5%
22.24
US$120,437 		5,416 -7.5% 22.24 US$120,437
2024-01-22 2024-01-22 PrS Proposed sale
2.8
DAVID S JONES

Officer

Officer
38,541
22.32
US$860,235 		38,541 22.32 US$860,235
2024-01-16 2024-01-11 S Sale
2.0
Liu Ye
Non-Executive Director
1,910,500 -95.0%
19.45
US$37,159,225 		1,910,500 -95.0% 19.45 US$37,159,225
2024-01-16 2024-01-11 S Sale
1.7
Ocumension Therapeutics
Non-Executive Director
1,910,500 -95.0%
19.45
US$37,159,225 		1,910,500 -95.0% 19.45 US$37,159,225
2024-01-11 2024-01-11 PrS Proposed sale
1.7
Ocumension Therapeutics

Director

Non-Executive Director
1,910,500
19.45
US$37,159,225 		1,910,500 19.45 US$37,159,225
2024-01-11 2024-01-11 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
750,000 +12.2%
19.75
US$14,812,500 		750,000 +12.2% 19.75 US$14,812,500
2024-01-11 2024-01-09 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
105,000 +1.7%
21.32
US$2,238,600 		105,000 +1.7% 21.32 US$2,238,600
2024-01-10 2024-01-08 S Sale
2.9
Paggiarino Dario A.

Chief Medical Officer

Officer
22,913 -38.6%
21.13
US$484,124 		22,913 -38.6% 21.13 US$484,124
2023-12-15 2023-12-13 S Sale
2.9
Paggiarino Dario A.

Chief Medical Officer

Officer
1,458 -5.4%
20.00
US$29,160 		1,458 -5.4% 20.00 US$29,160
2023-12-12 2023-12-08 B Purchase
3.8
Cormorant Asset Management, LP
Large shareholder
588,235 +10.8%
17.00
US$9,999,995 		588,235 +10.8% 17.00 US$9,999,995
2023-12-07 2023-12-06 S Sale
2.0
Liu Ye
Non-Executive Director
266,242 -11.7%
18.41
US$4,901,515 		266,242 -11.7% 18.41 US$4,901,515
2023-12-07 2023-12-06 S Sale
1.7
Ocumension Therapeutics
Non-Executive Director
266,242 -11.7%
18.41
US$4,901,515 		266,242 -11.7% 18.41 US$4,901,515
2023-12-07 2023-12-05 S Sale
2.0
Liu Ye
Non-Executive Director
733,758 -24.4%
19.91
US$14,609,122 		733,758 -24.4% 19.91 US$14,609,122
2023-12-07 2023-12-05 S Sale
1.7
Ocumension Therapeutics
Non-Executive Director
733,758 -24.4%
19.91
US$14,609,122 		733,758 -24.4% 19.91 US$14,609,122
2023-12-05 2023-12-05 PrS Proposed sale
1.7
Ocumension Therapeutics

Director

Non-Executive Director
1,000,000
18.34
US$18,340,000 		1,000,000 18.34 US$18,340,000
Explore more

More insider trading research around EyePoint Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Pharmaceuticals companies with insider activity
Insider trading in North America